Citi raises Ultragenyx price target to $58 after FDA approval

August 20, 2026 5:04 AM

Citi analyst Yigal Nochomovitz raised the price target on Ultragenyx Pharmaceutical (NASDAQ: RARE) to $58 from $45, while maintaining a ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found